1108 related articles for article (PubMed ID: 35405385)
21. Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters.
Su W; Choy KT; Gu H; Sia SF; Cheng KM; Nizami SIN; Krishnan P; Ng YM; Chang LDJ; Liu Y; Cheng SMS; Peiris M; Poon LLM; Nicholls JM; Yen HL
J Infect Dis; 2023 May; 227(10):1143-1152. PubMed ID: 35776136
[TBL] [Abstract][Full Text] [Related]
22. Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters.
Abdelnabi R; Lassaunière R; Maes P; Weynand B; Neyts J
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257822
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters.
Mohandas S; Yadav PD; Shete A; Nyayanit D; Sapkal G; Lole K; Gupta N
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578354
[TBL] [Abstract][Full Text] [Related]
24. Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model.
Yadav P; Mohandas S; Sarkale P; Nyayanit D; Shete A; Sahay R; Potdar V; Baradkar S; Gupta N; Sapkal G; Abraham P; Panda S; Bhargava B
J Infect Public Health; 2022 Feb; 15(2):164-171. PubMed ID: 34959053
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Imai M; Halfmann PJ; Yamayoshi S; Iwatsuki-Horimoto K; Chiba S; Watanabe T; Nakajima N; Ito M; Kuroda M; Kiso M; Maemura T; Takahashi K; Loeber S; Hatta M; Koga M; Nagai H; Yamamoto S; Saito M; Adachi E; Akasaka O; Nakamura M; Nakachi I; Ogura T; Baba R; Fujita K; Ochi J; Mitamura K; Kato H; Nakajima H; Yagi K; Hattori SI; Maeda K; Suzuki T; Miyazato Y; Valdez R; Gherasim C; Furusawa Y; Okuda M; Ujie M; Lopes TJS; Yasuhara A; Ueki H; Sakai-Tagawa Y; Eisfeld AJ; Baczenas JJ; Baker DA; O'Connor SL; O'Connor DH; Fukushi S; Fujimoto T; Kuroda Y; Gordon A; Maeda K; Ohmagari N; Sugaya N; Yotsuyanagi H; Mitsuya H; Suzuki T; Kawaoka Y
Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34140350
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters.
Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani H; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
bioRxiv; 2023 May; ():. PubMed ID: 37205409
[TBL] [Abstract][Full Text] [Related]
27. Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants.
Feng S; Fan Z; Zhou K; Ma S; Liang M; Zhang H; Xie Y; Ha Z; Jin N; Lu H
J Med Virol; 2023 Oct; 95(10):e29160. PubMed ID: 37822266
[TBL] [Abstract][Full Text] [Related]
28. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
[TBL] [Abstract][Full Text] [Related]
29. Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters.
Mohandas S; Shete A; Kumar A; Wakchaure K; Rai V; Mote C; Dighe H; Sarkale P; Gawande P; Yemul J; Suryawanshi A; Joshi Y; Yadav PD
Front Microbiol; 2023; 14():1183763. PubMed ID: 37426033
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants.
Bauer L; Rissmann M; Benavides FFW; Leijten L; van Run P; Begeman L; Veldhuis Kroeze EJB; Lendemeijer B; Smeenk H; de Vrij FMS; Kushner SA; Koopmans MPG; Rockx B; van Riel D
Acta Neuropathol Commun; 2022 Sep; 10(1):124. PubMed ID: 36058935
[TBL] [Abstract][Full Text] [Related]
31. Comparison of SARS-CoV-2 Variants of Concern 202012/01 (U.K. Variant) and D614G Variant Transmission by Different Routes in Syrian Hamsters.
Mohandas S; Yadav PD; Nyayanit D; Shete A; Sarkale P; Hundekar S; Kumar S; Lole K
Vector Borne Zoonotic Dis; 2021 Aug; 21(8):638-641. PubMed ID: 34197265
[No Abstract] [Full Text] [Related]
32. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge.
Zhou B; Zhou R; Tang B; Chan JF; Luo M; Peng Q; Yuan S; Liu H; Mok BW; Chen B; Wang P; Poon VK; Chu H; Chan CC; Tsang JO; Chan CC; Au KK; Man HO; Lu L; To KK; Chen H; Yuen KY; Dang S; Chen Z
Nat Commun; 2022 Jun; 13(1):3589. PubMed ID: 35739114
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
[TBL] [Abstract][Full Text] [Related]
34. Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection.
Pidal P; Fernández J; Airola C; Araujo M; Menjiba AM; Martín HS; Bruneau N; Balanda M; Elgueta C; Fasce R; Valenzuela MT; Orellana A; Ramírez E
Med Microbiol Immunol; 2023 Feb; 212(1):25-34. PubMed ID: 36370196
[TBL] [Abstract][Full Text] [Related]
35. BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.
Singh J; Anantharaj A; Panwar A; Rani C; Bhardwaj M; Kumar P; Chattopadhyay P; Devi P; Maurya R; Mishra P; Pandey AK; Pandey R; Medigeshi GR
PLoS Pathog; 2023 Feb; 19(2):e1011196. PubMed ID: 36827451
[TBL] [Abstract][Full Text] [Related]
36. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
Zhang QY; Zhang HQ; Zhang YN; Zhang ZR; Li XD; Hao MC; Zhang Y; Li JQ; Hu YY; Chen XL; Wang J; Shi YJ; Deng CL; Chen JJ; Ye HQ; Zhang B
Antiviral Res; 2023 Dec; 220():105757. PubMed ID: 37984567
[TBL] [Abstract][Full Text] [Related]
37. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
O'Donnell KL; Pinski AN; Clancy CS; Gourdine T; Shifflett K; Fletcher P; Messaoudi I; Marzi A
EBioMedicine; 2021 Nov; 73():103675. PubMed ID: 34758415
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.
Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L
Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904
[TBL] [Abstract][Full Text] [Related]
40. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
